Nishida Tomoyuki - Novo Nordisk Pharma Ltd

基本信息

浏览量：9

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 26 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Efficacy and Safety of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin in Japanese Individuals with Type 2 Diabetes: A Subgroup Analysis of the ONWARDS 1, 2 and 4 Trials

Hirotaka Watada,Bjorg Asbjornsdottir,Tomoyuki Nishida,Rimei Nishimura,Yuiko Yamamoto,Toshimasa Yamauchi,Takashi Kadowaki

DIABETES OBESITY & METABOLISM (2024)

引用0浏览0WOS引用

Continuous Glucose Monitoring-Based Metrics and the Duration of Hypoglycaemia Events with Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naive Type 2 Diabetes: an Exploratory Analysis of ONWARDS 1

Richard M Bergenstal,Björg Ásbjörnsdóttir, Sara K Watt,Ildiko Lingvay, Julia K Mader,Tomoyuki Nishida,Julio Rosenstock

The Lancet Diabetes & Endocrinology（2024）

引用0浏览0WOS引用

CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D: ONWARDS 1 Exploratory Analysis

Richard Bergenstal, Sara Kehlet Watt,Ana Laura S. A. Matos,Ildiko Lingvay,Julia K. Mader,Tomoyuki Nishida,Julio Rosenstock

Diabetologie und Stoffwechsel (2024)

引用0浏览0引用

Richard M. Bergenstal,Bjorg Asbjornsdottir, Sara K. Watt,Ildiko Lingvay,Julia K. Mader,Tomoyuki Nishida,Julio Rosenstock

LANCET DIABETES & ENDOCRINOLOGYno. 11 (2024): 799-810

引用0浏览0引用

Weekly Icodec Versus Daily Glargine U100 in Type 2 Diabetes Without Previous Insulin

Julio Rosenstock,Stephen C. Bain,Amoolya Gowda,Esteban Jodar, Bo Liang,Ildiko Lingvay,Tomoyuki Nishida,Roberto Trevisan,Ofri Mosenzon

NEW ENGLAND JOURNAL OF MEDICINEno. 4 (2023): 297-308

引用8浏览0WOS引用

Semaglutide Once a Week in Adults with Overweight or Obesity, with or Without Type 2 Diabetes in an East Asian Population (STEP 6): a Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3a Trial

Takashi Kadowaki,Joakim Isendahl,Usman Khalid,Sang Yeoup Lee,Tomoyuki Nishida,Wataru Ogawa,Kazuyuki Tobe,Toshimasa Yamauchi,Soo Lim

The Lancet Diabetes & Endocrinology（2022）

引用65浏览0WOS引用

Efficacy and Safety of Once‐weekly Semaglutide in Japanese Individuals with Type 2 Diabetes in the SUSTAIN 1, 2, 5 and 9 Trials: Post‐hoc Analysis

Eiichi Araki,Shinichi Harashima,Tomoyuki Nishida,Jiro Nakamura

Journal of Diabetes Investigation（2022）

引用2浏览0WOS引用

Efficacy and Safety of Once‐weekly Semaglutide in Japanese Individuals with Type 2 Diabetes by Baseline Age and Body Mass Index

Daisuke Yabe,Yuichiro Yamada,Kohei Kaku,Tomoyuki Nishida,Toshihiro Sato,Yutaka Seino

Journal of diabetes investigation（2022）

引用6浏览0WOS引用

Efficacy and Safety of the Fixed‐ratio Combination of Insulin Degludec and Liraglutide by Baseline Glycated Hemoglobin, Body Mass Index and Age in Japanese Individuals with Type 2 Diabetes: A Subgroup Analysis of Two Phase III Trials

Mitsuhisa Komatsu,Hirotaka Watada,Shizuka Kaneko,Bue F. Ross Agner,Tomoyuki Nishida,Kohei Kaku

Journal of Diabetes Investigation（2021）

引用7浏览0WOS引用

DUAL II China: Superior HbA1c Reductions and Weight Loss with Insulin Degludec/liraglutide (ideglira) Versus Insulin Degludec in a Randomized Trial of Chinese People with Type 2 Diabetes Inadequately Controlled on Basal Insulin

Yu Pei, Bue R. Agner,Bin Luo,Xiaolin Dong,Dongmei Li, Jun Liu,Lei Liu,Ming Liu,Yibing Lu,Tomoyuki Nishida,Xiangjin Xu,Yiming Mu

Diabetes Obesity and Metabolismno. 12 (2021): 2687-2696

引用11浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn